Search

Your search keyword '"Mascola, John"' showing total 669 results

Search Constraints

Start Over You searched for: Author "Mascola, John" Remove constraint Author: "Mascola, John" Search Limiters Peer Reviewed Remove constraint Search Limiters: Peer Reviewed
669 results on '"Mascola, John"'

Search Results

1. Phase 1 dose-escalation trial evaluating a group 2 influenza hemagglutinin stabilized stem nanoparticle vaccine

2. Administration of anti-HIV-1 broadly neutralizing monoclonal antibodies with increased affinity to Fcγ receptors during acute SHIVAD8-EO infection

3. Heterologous cAd3-Ebola and MVA-EbolaZ vaccines are safe and immunogenic in US and Uganda phase 1/1b trials

4. Cleavage-intermediate Lassa virus trimer elicits neutralizing responses, identifies neutralizing nanobodies, and reveals an apex-situated site-of-vulnerability

5. Safety and pharmacokinetics of VRC07-523LS administered via different routes and doses (HVTN 127/HPTN 087): A Phase I randomized clinical trial

7. Cholesterol reduction by immunization with a PCSK9 mimic

8. SARS-CoV-2 recombinant spike ferritin nanoparticle vaccine adjuvanted with Army Liposome Formulation containing monophosphoryl lipid A and QS-21: a phase 1, randomised, double-blind, placebo-controlled, first-in-human clinical trial

9. Antibody-directed evolution reveals a mechanism for enhanced neutralization at the HIV-1 fusion peptide site

10. Self-assembling SARS-CoV-2 spike-HBsAg nanoparticles elicit potent and durable neutralizing antibody responses via genetic delivery

11. Trispecific antibody targeting HIV-1 and T cells activates and eliminates latently-infected cells in HIV/SHIV infections

12. Frequency-potency analysis of IgG+ memory B cells delineates neutralizing antibody responses at single-cell resolution

13. Long trimer-immunization interval and appropriate adjuvant reduce immune responses to the soluble HIV-1-envelope trimer base

14. Safety, tolerability, and immunogenicity of the Ebola Sudan chimpanzee adenovirus vector vaccine (cAd3-EBO S) in healthy Ugandan adults: a phase 1, open-label, dose-escalation clinical trial

15. Risk of COVID-19 after natural infection or vaccination

16. Soluble prefusion-closed HIV-envelope trimers with glycan-covered bases

17. Pharmacokinetic serum concentrations of VRC01 correlate with prevention of HIV-1 acquisition

19. Safety, tolerability, and immunogenicity of the chimpanzee adenovirus type 3-vectored Marburg virus (cAd3-Marburg) vaccine in healthy adults in the USA: a first-in-human, phase 1, open-label, dose-escalation trial

20. Interprotomer disulfide-stabilized variants of the human metapneumovirus fusion glycoprotein induce high titer-neutralizing responses

21. Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial

22. Safety and tolerability of AAV8 delivery of a broadly neutralizing antibody in adults living with HIV: a phase 1, dose-escalation trial

23. Co-immunization with hemagglutinin stem immunogens elicits cross-group neutralizing antibodies and broad protection against influenza A viruses

25. Safety and immunogenicity of a trivalent virus-like particle vaccine against western, eastern, and Venezuelan equine encephalitis viruses: a phase 1, open-label, dose-escalation, randomised clinical trial

26. Safety and immunogenicity of an HIV-1 prefusion-stabilized envelope trimer (Trimer 4571) vaccine in healthy adults: A first-in-human open-label, randomized, dose-escalation, phase 1 clinical trial

27. Safety and immunogenicity of a ferritin nanoparticle H2 influenza vaccine in healthy adults: a phase 1 trial

28. A single residue in influenza virus H2 hemagglutinin enhances the breadth of the B cell response elicited by H2 vaccination

29. Engineering of HIV-1 neutralizing antibody CAP256V2LS for manufacturability and improved half life

30. First-in-human immunoPET imaging of HIV-1 infection using 89Zr-labeled VRC01 broadly neutralizing antibody

31. Primary exposure to SARS-CoV-2 variants elicits convergent epitope specificities, immunoglobulin V gene usage and public B cell clones

33. A multiclade env–gag VLP mRNA vaccine elicits tier-2 HIV-1-neutralizing antibodies and reduces the risk of heterologous SHIV infection in macaques

34. Structural basis of glycan276-dependent recognition by HIV-1 broadly neutralizing antibodies

35. Fc-mediated effector function contributes to the in vivo antiviral effect of an HIV neutralizing antibody

36. Safety, tolerability, and immunogenicity of the respiratory syncytial virus prefusion F subunit vaccine DS-Cav1: a phase 1, randomised, open-label, dose-escalation clinical trial

37. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7

38. Quadrivalent influenza nanoparticle vaccines induce broad protection

39. Structure-based design of a quadrivalent fusion glycoprotein vaccine for human parainfluenza virus types 1–4

41. Neutralizing antibody VRC01 failed to select for HIV-1 mutations upon viral rebound

42. Infusion Reactions After Receiving the Broadly Neutralizing Antibody VRC01 or Placebo to Reduce HIV-1 Acquisition: Results From the Phase 2b Antibody-Mediated Prevention Randomized Trials

43. Antibody Fc effector functions and IgG3 associate with decreased HIV-1 risk

44. Glycan-dependent HIV-specific neutralizing antibodies bind to cells of uninfected individuals

45. SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness

46. Safety and pharmacokinetics of broadly neutralising human monoclonal antibody VRC07-523LS in healthy adults: a phase 1 dose-escalation clinical trial

47. Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a phase 2, randomised, double-blind, placebo-controlled trial

48. Characterization of the Neutralizing Antibody Response in a Case of Genetically Linked HIV Superinfection

49. A Phase 2b Study to Evaluate the Safety and Efficacy of VRC01 Broadly Neutralizing Monoclonal Antibody in Reducing Acquisition of HIV-1 Infection in Women in Sub-Saharan Africa: Baseline Findings

50. Feasibility and Successful Enrollment in a Proof-of-Concept HIV Prevention Trial of VRC01, a Broadly Neutralizing HIV-1 Monoclonal Antibody

Catalog

Books, media, physical & digital resources